Obstetrics and gynecology
-
Obstetrics and gynecology · Apr 2015
Comparative StudyPerinatal outcomes with normal compared with elevated umbilical artery systolic-to-diastolic ratios in fetal growth restriction.
To compare the composite neonatal morbidity of pregnancies with fetal growth restriction (estimated fetal weight less than the 10th percentile) and normal compared with elevated umbilical artery systolic-to-diastolic ratios. ⋯ Composite neonatal morbidity is comparable in fetal growth-restricted pregnancies with elevated compared with normal umbilical artery systolic-to-diastolic ratios when delivered at 37 and 39 weeks of gestation, respectively. Planning delivery of pregnancies with fetal growth restriction and elevated systolic-to-diastolic ratios and without other complications at 37 weeks of gestation results in good outcomes.
-
Obstetrics and gynecology · Apr 2015
Validation of a vaginal birth after cesarean delivery prediction model in women with two prior cesarean deliveries.
To evaluate whether an existing vaginal birth after cesarean delivery (VBAC) prediction model validated for women with one prior cesarean delivery also accurately predicts the likelihood of VBAC in women with two prior cesarean deliveries. ⋯ The estimates of VBAC success based on the MFMU prediction model are similar to the actual rates observed among women with two prior cesarean deliveries.
-
Obstetrics and gynecology · Apr 2015
Suicide risk among perinatal women who report thoughts of self-harm on depression screens.
To estimate the incidence and clinical significance of suicidal ideation revealed during perinatal depression screening and estimate the associated suicide risk. ⋯ Among perinatal women screened for depression, 3.8% reported suicidal ideation, but only 1.1% of this subgroup was at high risk for suicide. These findings support the need for systematic evaluation of those who report suicidal ideation to identify the small subset requiring urgent evaluation and care.
-
Obstetrics and gynecology · Mar 2015
Editorial ReviewUnderrepresentation of women in clinical trials: why gynecologic oncologists are worried.
In gynecologic oncology, significant advances with improved patient outcomes have clearly and thankfully resulted from randomized clinical trials. The recent restructuring of cooperative groups and decreased funding for phase III clinical trials have unintentionally resulted in a 90% reduction of available trials and accrual in gynecologic oncology. ⋯ We suggest an opportunity for partnering with the U. S. government and the private sector to enhance research funding opportunities while increasing advocacy efforts to reinvigorate our clinical trials platform.